Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT1, 2008, Pages 1036-1045

  Chang, David K ^b   Merrett, Neil D ^b   Biankin, Andrew V ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b NONE

Author keywords

Outcome; Pancreatic cancer; Pancreatic surgery; Pancreatology; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HEALTH CARE QUALITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 47649101549     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05471.x     Document Type: Review

References (103)

1. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (AACR). Cancer in Australia 2001. Canberra : AIHW, 2004.
2. Yeo CJ, Cameron JL, Sohn TA et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann. Surg. 1997 226 : 248 57.
3. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004 350 : 1200 10.
4. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann. Surg. 2006 244 : 10 15.
5. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann. Surg. 1935 102 : 79.
6. Whipple AO. The rationale of radical surgery for cancer of the pancreas and ampullary region. Ann. Surg. 1941 114 : 15.
7. Crile G Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg. Gynecol Obstet. 1970 130 : 1049 53.
8. Gudjonsson B. Cancer of the pancreas 50 years of surgery. Cancer 1987 60 : 2284 303.
9. Shapiro TM. Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs Whipple resection in good risk patients. Ann. Surg. 1975 182 : 715 21.
10. Martignoni ME, Wagner M, Krahenbuhl L, Redaelli CA, Friess H, Buchler MW. Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am. J. Surg. 2001 181 : 52 9.
11. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest Surg. 2000 4 : 567 79.
12. Balcom IV, James H, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch. Surg. 2001 136 : 391.
13. Pisters PW, Hudec WA, Hess KR et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann. Surg. 2001 234 : 47 55.
14. Sewnath ME, Birjmohun RS, Rauws EA, Huibregtse K, Obertop H, Gouma DJ. The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy. J. Am. Coll. Surg. 2001 192 : 726 34.
15. Povoski SP, Karpeh MS, Conlon KC, Blumgart LH, Brennan MF. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann. Surg. 1999 230 : 131 42.
16. Engel AF, Oomen JL, Knol DL, Cuesta MA. Operative mortality after colorectal resection in the Netherlands. Br. J. Surg. 2005 92 : 1526 32.
17. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann. Surg. 2007 246 : 173 80.
18. Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N. Engl. J. Med. 1979 301 : 1364 9.
19. Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann. Surg. 2003 237 : 509 14.
20. Lieberman M, Kilburn H, Lindsey M, Brennan M. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann. Surg. 1995 222 : 638 45.
21. Sosa JA, Bowman HM, Gordon TA et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann. Surg. 1998 228 : 429 38.
22. The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. A Policy Framework for Commissioning Cancer Services: A Report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. Guidance for Providers and Purchasers of Cancer Services. London : Department of Health, 1995.
23. National Cancer Guidance Steering Group. Improving Outcomes in Upper Gastrointestinal Cancers. The Research Evidence NHS Executive. London : Department of Health, 2001.
24. National Cancer Guidance Steering Group. Improving Outcomes in Upper Gastrointestinal Cancers. The Manual NHS Executive. London : Department of Health, 2001.
25. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann. Intern. Med. 2002 137 : 511 20.
26. Finlayson EVA, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery a national study. Arch. Surg. 2003 138 : 721 5.
27. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999 126 : 178 83.
28. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann. Surg. 2007 245 : 777 83.
29. Finlayson EVA, Birkmeyer JD. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J. Am. Coll Surgeons 2003 196 : 410 17.
30. Goodney PP, Stukel TA, Lucas FL, Finlayson EV, Birkmeyer JD. Hospital volume, length of stay, and readmission rates in high-risk surgery. Ann. Surg. 2003 238 : 161 7.
31. Andren-Sandberg A, Neoptolemos JP. Resection for pancreatic cancer in the new millennium. Pancreatology 2002 2 : 431 9.
32. Gouma DJ, van Geenen RC, van Gulik TM et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann. Surg. 2000 232 : 786 95.
33. Simunovic M, To T, Theriault M, Langer B. Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system. Can. Med. Assoc. J. 1999 160 : 643 8.
34. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N. Engl. J. Med. 2003 349 : 2117 27.
35. Lillemoe KD, Sauter PK, Pitt HA, Yeo CJ, Cameron JL. Current status of surgical palliation of periampullary carcinoma. Surg. Gynecol Obstet. 1993 176 : 1 10.
36. Kelsen DP, Portenoy R, Thaler H, Tao Y, Brennan M. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997 122 : 53 9.
37. de Rooij PD, Rogatko A, Brennan MF. Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br. J. Surg. 1991 78 : 1053 8.
38. Soriano A, Castells A, Ayuso C et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am. J. Gastroenterol 2004 99 : 492 501.
39. Raut CP, Grau AM, Staerkel GA et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J. Gastrointest Surg. 2003 7 : 118 28.
40. Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom. Imaging. 2007 32 : 660 7.
41. Arslan A, Buanes T, Geitung JT. Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur. J. Radiol 2001 38 : 151 9.
42. Nishiharu T, Yamashita Y, Abe Y et al. Local extension of pancreatic carcinoma: assessment with thin-section helical CT versus with breath-hold fast MR imaging - ROC analysis. Radiology. 1999 212 : 445 52.
43. Ichikawa T, Haradome H, Hachiya J et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997 202 : 655 62.
44. Samra JS, Biankin AV, Merrett ND. Role of endoscopic ultrasound in the management of pancreatic lesions. ANZ J. Surg. 2008 78 : 315 6.
45. Micames C, Jowell PS, White R et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs percutaneous FNA. Gastrointest. Endosc. 2003 58 : 690 5.
46. Paquin SC, Gariepy G, Lepanto L, Bourdages R, Raymond G, Sahai AV. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest. Endosc. 2005 61 : 610 11.
47. Pisters PWT, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br. J. Surg. 2001 88 : 325 37.
48. Barreiro CJ, Lillemoe KD, Koniaris LG et al. Diagnostic laparoscopy for periampullary and pancreatic cancer: what is the true benefit? J. Gastrointest Surg. 2002 6 : 75 81.
49. Hennig R, Tempia-Caliera AA, Hartel M, Buchler MW, Friess H. Staging laparoscopy and its indications in pancreatic cancer patients. Dig. Surg. 2002 19 : 484 8.
50. Tilleman E, Busch ORC, Bemelman WA, van Gulik TM, Obertop H, Gouma DJ. Diagnostic laparoscopy in staging pancreatic carcinoma: developments during the past decade. J. Hepato-Biliary-Pancreatic Surg. 2004 11 : 11 16.
51. van Dijkum EJN, Romijn MG, Terwee CB et al. Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. Ann. Surg. 2003 237 : 66 73.
52. National Comprehensive Cancer Network. Practice Guidelines for Pancreatic Cancer. Cited 15 Sep 2007. Available from URL: http://www.nccn.org
53. Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann. Surg. 2007 246 : 52 60.
54. Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. 2001 234 : 758 68.
55. Millikan KW, Deziel DJ, Silverstein JC et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am. Surg. 1999 65 : 618 23.
56. Nishimura Y, Hosotani R, Shibamoto Y et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int. J. Radiat. Oncol. Biol. Phys. 1997 39 : 39 49.
57. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br. J. Surg. 1996 83 : 625 31.
58. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Ann. Surg. 1995 221 : 59 66.
59. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas Implications for radiation therapy. Ann. Surg. 1993 217 : 144 8.
60. Fortner J. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 1973 73 : 307 20.
61. Tseng JF, Raut CP, Lee JE et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J. Gastrointest. Surg. 2004 8 : 935 50.
62. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma A contraindication for resection? Ann. Surg. 1996 224 : 342 7.
63. Hartel M, Niedergethmann M, Farag-Soliman M et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur. J. Surg. 2002 168 : 707 12.
64. Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer outcomes and implications for therapy. Arch. Surg. 2003 138 : 1316 22.
65. Bachellier P, Nakano H, Oussoultzoglou PD et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am. J. Surg. 2001 182 : 120 9.
66. Roder JD, Stein HJ, Siewert JR. Carcinoma of the periampullary region: who benefits from portal vein resection? Am. J. Surg. 1996 171 : 170 4.
67. Takahashi S, Ogata Y, Tsuzuki T. Combined resection of the pancreas and portal vein for pancreatic cancer. Br. J. Surg. 1994 81 : 1190 3.
68. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R. Extended resections of ductal pancreatic cancer - impact on operative risk and prognosis. Oncology 1996 53 : 47 53.
69. Shibata C, Kobari M, Tsuchiya T et al. Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas. World J. Surg. 2001 25 : 1002 5.
70. Allema JH, Reinders ME, van Gulik TM et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br. J. Surg. 1994 81 : 1642 6.
71. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J. Gastrointest. Surg. 2006 10 : 1106 15.
72. Carrère N, Sauvanet A, Goere D et al. Pancreaticoduodenectomy with mesentericoportal vein resection for adenocarcinoma of the pancreatic head. World J. Surg. 2006 30 : 1526 35.
73. Nakao A, Takeda S, Inoue S et al. Indications and techniques of extended resection for pancreatic cancer. World J. Surg. 2006 30 : 976 82.
74. Siriwardana HPP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br. J. Surg. 2006 93 : 662 73.
75. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin. Cancer Res. 2000 6 : 2969 72.
76. Hruban RH, Wilentz RE, Goggins M, Offerhaus GJA, Yeo CJ, Kern SE. Pathology of incipient pancreatic cancer. Ann. Oncol. 1999 10 : 9 11.
77. Biankin AV, Biankin SA, Kench JG et al. Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 2002 50 : 861 8.
78. Biankin AV, Kench JG, Biankin SA et al. Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am. J. Surg. Pathol. 2004 28 : 1184 92.
79. Castillo CF, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch. Surg. 2003 138 : 427.
80. Katz DS, Friedel DM, Kho D, Georgiou N, Hines JJ. Relative accuracy of CT and MRI for characterization of cystic pancreatic masses. AJR Am. J. Roentgenol. 2007 189 : 657 61.
81. Hruban RH, Takaori K, Klimstra DS et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 2004 28 : 977 87.
82. Longnecker DS, Adler G, Hruban RH, Kloppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In : WHO Classification of Tumors of the Digestive System. Lyon : IARC Press, 2000 237 40.
83. Hruban RH, Adsay NV, Albores-Saavedra J et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001 25 : 579 86.
84. Takaori K. Dilemma in classifications of possible precursors of pancreatic cancer involving the main pancreatic duct: PanIN or IPMN? J. Gastroenterol. 2003 38 : 311 13.
85. Adsay NV. The 'new kid on the block': intraductal papillary mucinous neoplasms of the pancreas: current concepts and controversies. Surgery 2003 133 : 459 63.
86. Tollefson MK, Libsch KD, Sarr MG et al. Intraductal papillary mucinous neoplasm: did it exist prior to 1980? Pancreas. 2003 26 : e55 8.
87. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann. Surg. 2001 234 : 313 21.
88. Salvia R, Fernandez-del Castillo C, Bassi C et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann. Surg. 2004 239 : 678 85.
89. Chari ST, Yadav D, Smyrk TC et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002 123 : 1500 7.
90. Wilentz RE, Albores-Saavedra J, Hruban RH. Mucinous cystic neoplasms of the pancreas. Semin. Diagn. Pathol. 2000 17 : 31 42.
91. Albores-Saavedra J, Angeles-Angeles A, Nadji M, Henson DE, Alvarez L. Mucinous cystadenocarcinoma of the pancreas morphologic and immunocytochemical observations. Am. J. Surg. Pathol. 1987 11 : 11 20.
92. Wilentz RE, Albores-Saavedra J, Zahurak M et al. Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am. J. Surg. Pathol. 1999 23 : 1320 7.
93. Sarr MG, Carpenter HA, Prabhakar LP et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms. Ann. Surg. 2000 231 : 205 12.
94. Tanaka M, Chari S, Adsay V et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas Pancreatology 2006 6 : 17 32.
95. Biankin AV, Morey AL, Lee CS et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J. Clin. Oncol. 2002 20 : 4531 42.
96. Segara D, Biankin AV, Kench JG et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin. Cancer Res. 2005 11 : 3587 96.
97. Biankin AV, Kench JG, Segara D et al. Use of the novel biomarker (HOXB2) to predict response to pancreatectomy for pancreatic cancer. J. Clin. Oncol. 2007 25 : 10526.
98. Skalicky DA, Kench JG, Segara D et al. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomark Prev. 2006 15 : 1941.
99. Biankin AV, Kench JG, Dijkman FP, Biankin SA, Henshall SM. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 2003 35 : 14 24.
100. Biankin AV, Kench JG, Morey AL et al. Overexpression of p21WAF1/CIP1 is an early event in the development of pancreatic intraepithelial neoplasia 1. Cancer Res. 2001 61 : 8830 7.
101. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin. Oncol. 2007 34 : 284 94.
102. Canto MI. Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin. Oncol. 2007 34 : 295 302.
103. New South Wales Pancreatic Cancer Network. About Pancreatic Cancer. Cited 15 Nov 2007. Available from URL: http://www.pancreaticcancer.net.au